HCP

CEO Appointed at Clasado Biosciences

Former Commercial Director of OptiBiotix Health Plc, Per Rehné has been appointed Chief Executive Officer of Clasado Biosciences. 

Clasado is a pioneer and leading biotechnology company, developing microbiome products aimed at consumers Gastrointestinal wellness for the food and healthcare sectors, including the unique commercialised prebiotic, Bimuno®.

Rehné said of his appointment as CEO: “I’m pleased to be joining Clasado at a key time in the company’s history. With over 15 years of scientific research and experience in the development of its global IP position for gut wellness solutions, and the increasing growth in focus on health and wellbeing by consumers, the future looks bright for the company.”

Having built expertise in the health and nutrition sector over 20+ years in the Nordic Countries and in later years in the UK at Cornelius Group Plc and latterly OptiBiotix Health Plc, where he remains a Non-Executive Director of the ProBiotix Health Division, Rehné is well placed to build the fortunes of the leading biosciences organisation.

Moncef Slaoui, Chairman of Clasado said: “Per has an enviable track record in delivering strategic growth and we are delighted he agreed to head up our team. As our new CEO, Per is responsible for shaping our business strategy going forward and we are excited about the potential he sees for our products and innovation pipeline.”

To find out more about Clasado Biosciences, please visit www.clasado.com